EurekAlert! Cancer Research - News Releases

News Releases

Updates every hour. Last Updated: 15-Dec-2025 23:11 ET (16-Dec-2025 04:11 GMT/UTC)

Research team visualizes chemical signals of individual cells

University of Münster
Peer-Reviewed Publication

How do cells in tumour tissue communicate with each other, and what can we learn about cancer from this? A research team at the Institute of Hygiene at the University of Münster has developed a method combining fluorescence microscopy and imaging mass spectrometry. This reveals metabolic differences between individual cells for the first time, representing a breakthrough in diagnosis and therapy. The results have been published in the journal Nature Communications.

Journal: Nature Communications

New platform for the production of versatile active ingredients

Helmholtz Centre for Infection Research
Peer-Reviewed Publication

Natural products derived from microorganisms are a promising source of new active ingredients, but are often produced only in very small quantities. A research team from the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) led by Tobias Gulder has now succeeded in establishing a chemo-enzymatic platform for the production of furanolides – a class of natural products with a broad spectrum of activity. This strategy not only allows furanolides to be produced cost-effectively, but also enables structural modifications to be made. The newly generated molecules are capable of effectively combating both bacterial pathogens and cancer cells. The team has now published its findings in the Journal of the American Chemical Society.

Journal: Journal of the American Chemical Society

Combination of immunotherapy and targeted therapy improves survival for patients with advanced colorectal cancer

University of California - Los Angeles Health Sciences
Peer-Reviewed Publication

A new study led by UCLA investigators found that combining zanzalintinib, a targeted therapy drug, and atezolizumab, an immune checkpoint inhibitor, helped patients with metastatic colorectal cancer, the second most common cause of cancer death in the U.S., live longer and control their disease better than with the standard treatment drug regorafenib.

Journal: The Lancet
Meeting: ESMO 25

Graying hair may reflect a natural defense against cancer risk, new study finds

The Institute of Medical Science, The University of Tokyo
Peer-Reviewed Publication

Hair graying and melanoma—a form of skin cancer—may seem like unrelated phenomena. But according to a new study from The University of Tokyo, both outcomes may arise from how pigment-producing stem cells respond to DNA damage. These cells, located in hair follicles, face a critical decision under genotoxic stress: either to differentiate and exit the system—leading to graying—or to continue dividing, which may eventually lead to tumor formation.

Journal: Nature Cell Biology
Funder: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development

Research shows world-first breakthrough for bowel cancer immunotherapy

University of Galway
Peer-Reviewed Publication

Researchers at the University of Galway have revealed the results of a world-first study into how bowel cancer shuts down the immune system, and how this can be reversed to improve treatment.

The findings have been published in the Journal for ImmunoTherapy of Cancer (JITC).

The research team showed how structural stromal cells switch off the immune system and how the body’s own killer cells can be switched back on, opening up the opportunity for a completely new approach to optimising immunotherapy for patients.

Journal: Journal for ImmunoTherapy of Cancer

Experts urge risk-based monitoring as Barrett’s esophagus care moves beyond one-size-fits-all

American Gastroenterological Association
Peer-Reviewed Publication

Bethesda, MD (Oct. 17, 2025) — The American Gastroenterological Association (AGA) today released a new clinical practice guideline on the surveillance of Barrett’s esophagus, the only known precursor to esophageal cancer (adenocarcinoma), a highly lethal cancer whose incidence has risen substantially over recent decades. The guideline provides eight evidence-based recommendations and several key implementation statements to help clinicians monitor patients after a diagnosis of Barrett’s esophagus, a condition associated with chronic gastroesophageal reflux disease (GERD).

Journal: Gastroenterology

Combination therapy could expand treatment options for AML patients, extend survival

University of California - San Diego
Peer-Reviewed Publication

Proteasome inhibitors have proven highly effective in multiple myeloma but not in acute myeloid leukemia. The addition of a drug that inactivates the HSF1 pathway or impairs autophagy could change that.

Journal: Blood

Targeted diet enhances effects of new childhood cancer therapy

University of Zurich
Peer-Reviewed Publication

A research team from the University of Zurich and the University Children’s Hospital Zurich has developed a new approach for treating children with malignant tumors of the nervous system. By combining an approved drug with a specialized diet, they were able to slow down tumor growth and stimulate cancer cells to mature into normal nerve cells.

Journal: Nature

What is the extent of disparities in cancer clinical trials among low- and middle-income countries?

Wiley
Peer-Reviewed Publication

New research published by Wiley online in CANCER reveals that the number and complexity of cancer clinical trials since 2001 have varied across low- and middle-income countries, with economic growth contributing to disparities, but only to a certain extent.

Journal: Cancer

Immunotherapy after surgery shows promise in treating rare, aggressive skin cancer

NYU Langone Health / NYU Grossman School of Medicine
Reports and Proceedings

A drug that harnesses the immune system to attack cancer cells has proved successful in preventing a rare and aggressive form of skin cancer from spreading to other organs when given immediately after surgery, a new study shows.

Funder: NIH/National Institutes of Health
Meeting: European Society for Medical Oncology

65
66
67
68
69